This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.


This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.


This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

Norditropin banner

We’re Aiming Higher to Meet Your Expectations.
About Sogroya®

Sogroya® is a once-weekly growth hormone therapy for your paediatric patients with growth hormone deficiency.2

Dutch Parliament in The Hague, The Netherlands

We are excited to welcome you to The Hague, Netherlands, for the 61st Annual ESPE Meeting, taking place from September 21-23, 2023.


Novo Nordisk A/S. Growth Disorders. Available at: Last accessed: July 2023.


Novo Nordisk A/S. Growth Disorders. Available at: Last accessed: July 2023.


Sogroya® Summary of Product Characteristics. 2022:1-92.